Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology

dc.contributor.authorFernández Velasco, José I.
dc.contributor.authorMonreal, Enric
dc.contributor.authorKuhle, Jens
dc.contributor.authorMeca Lallana, Virginia
dc.contributor.authorMeca Lallana, José E.
dc.contributor.authorIzquierdo, Guillermo
dc.contributor.authorOreja-Guevara, Celia
dc.contributor.authorGascón Gimenez, Francisco
dc.contributor.authorSainz de la Maza, Susana
dc.contributor.authorWalo Delgado, Paulette E.
dc.contributor.authorLapuente Suanzes, Paloma
dc.contributor.authorMaceski, Aleksandra
dc.contributor.authorRodriguez Martín, Eulalia
dc.contributor.authorRoldán, Ernesto
dc.contributor.authorVillarrubia, Noelia
dc.contributor.authorSaiz Hinarejos, Albert
dc.contributor.authorBlanco, Yolanda
dc.contributor.authorDiaz Pérez, Carolina
dc.contributor.authorValero López, Gabriel
dc.contributor.authorDíaz Díaz, Judit
dc.contributor.authorAladro, Yolanda
dc.contributor.authorBrieva, Luis
dc.contributor.authorIñíguez, Cristina
dc.contributor.authorGonzález Suárez, Inés
dc.contributor.authorRodríguez de Antonio, Luis A.
dc.contributor.authorGarcía Domínguez, José M.
dc.contributor.authorSabin, Julia
dc.contributor.authorLlufriu Duran, Sara
dc.contributor.authorMasjuan, Jaime
dc.contributor.authorCosta Frossard, Lucienne
dc.contributor.authorVillar, Luisa M.
dc.date.accessioned2023-07-24T12:25:49Z
dc.date.available2023-07-24T12:25:49Z
dc.date.issued2022-03-21
dc.date.updated2023-07-19T09:42:57Z
dc.description.abstractTo ascertain the role of inflammation in the response to ocrelizumab in primary-progressive multiple sclerosis (PPMS).Multicenter prospective study including 69 patients with PPMS who initiated ocrelizumab treatment, classified according to baseline presence [Gd+, n=16] or absence [Gd-, n=53] of gadolinium-enhancing lesions in brain MRI. Ten Gd+ (62.5%) and 41 Gd- patients (77.4%) showed non-evidence of disease activity (NEDA) defined as no disability progression or new MRI lesions after 1 year of treatment. Blood immune cell subsets were characterized by flow cytometry, serum immunoglobulins by nephelometry, and serum neurofilament light-chains (sNfL) by SIMOA. Statistical analyses were corrected with the Bonferroni formula.More than 60% of patients reached NEDA after a year of treatment, regardless of their baseline characteristics. In Gd+ patients, it associated with a low repopulation rate of inflammatory B cells accompanied by a reduction of sNfL values 6 months after their first ocrelizumab dose. Patients in Gd- group also had low B cell numbers and sNfL values 6 months after initiating treatment, independent of their treatment response. In these patients, NEDA status was associated with a tolerogenic remodeling of the T and innate immune cell compartments, and with a clear increase of serum IgA levels.Baseline inflammation influences which immunological pathways predominate in patients with PPMS. Inflammatory B cells played a pivotal role in the Gd+ group and inflammatory T and innate immune cells in Gd- patients. B cell depletion can modulate both mechanisms.Copyright © 2022 Fernández-Velasco, Monreal, Kuhle, Meca-Lallana, Meca-Lallana, Izquierdo, Oreja-Guevara, Gascón-Giménez, Sainz de la Maza, Walo-Delgado, Lapuente-Suanzes, Maceski, Rodríguez-Martín, Roldán, Villarrubia, Saiz, Blanco, Diaz-Pérez, Valero-López, Diaz-Diaz, Aladro, Brieva, Íñiguez, González-Suárez, Rodríguez de Antonio, García-Domínguez, Sabin, Llufriu, Masjuan, Costa-Frossard and Villar.
dc.format.extent12 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idimarina9306915
dc.identifier.issn1664-3224
dc.identifier.pmid35386690
dc.identifier.urihttps://hdl.handle.net/2445/201067
dc.language.isoeng
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3389/fimmu.2022.842354
dc.relation.ispartofFrontiers In Immunology, 2022, vol. 13
dc.relation.urihttps://doi.org/10.3389/fimmu.2022.842354
dc.rightscc by (c) Fernández Velasco, José I. et al, 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
dc.subject.classificationEsclerosi múltiple
dc.subject.classificationImatges per ressonància magnètica
dc.subject.otherMultiple sclerosis
dc.subject.otherMagnetic resonance imaging
dc.titleBaseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved_FrontiersInImmunology.pdf
Mida:
1.6 MB
Format:
Adobe Portable Document Format